Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir
Here, the authors provide a mechanism for an improved version of a nanoformulated myristoylated prodrug of cabotegravir (CAB), named NM2CAB, and its bioavailability, stability and pharmacokinetics in mice and rats performed in independent academic and a contracted research labs, suggesting that the...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2bfe8aa999a043d6aa5d494a5ae8099d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:2bfe8aa999a043d6aa5d494a5ae8099d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:2bfe8aa999a043d6aa5d494a5ae8099d2021-12-02T14:58:13ZLipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir10.1038/s41467-021-23668-x2041-1723https://doaj.org/article/2bfe8aa999a043d6aa5d494a5ae8099d2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-23668-xhttps://doaj.org/toc/2041-1723Here, the authors provide a mechanism for an improved version of a nanoformulated myristoylated prodrug of cabotegravir (CAB), named NM2CAB, and its bioavailability, stability and pharmacokinetics in mice and rats performed in independent academic and a contracted research labs, suggesting that the extended half-life of the prodrug is not a property of enzymatic hydrolysis but rather release or dissolution of the prodrug from the nanocrystal.Nagsen GautamJoEllyn M. McMillanDevendra KumarAditya N. BadeQiaoyu PanTanmay A. KulkarniWenkuan LiBrady SillmanNathan A. SmithBhagya L. Dyavar ShettyAdam SzlachetkaBenson J. EdagwaHoward E. GendelmanYazen AlnoutiNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-13 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Nagsen Gautam JoEllyn M. McMillan Devendra Kumar Aditya N. Bade Qiaoyu Pan Tanmay A. Kulkarni Wenkuan Li Brady Sillman Nathan A. Smith Bhagya L. Dyavar Shetty Adam Szlachetka Benson J. Edagwa Howard E. Gendelman Yazen Alnouti Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir |
| description |
Here, the authors provide a mechanism for an improved version of a nanoformulated myristoylated prodrug of cabotegravir (CAB), named NM2CAB, and its bioavailability, stability and pharmacokinetics in mice and rats performed in independent academic and a contracted research labs, suggesting that the extended half-life of the prodrug is not a property of enzymatic hydrolysis but rather release or dissolution of the prodrug from the nanocrystal. |
| format |
article |
| author |
Nagsen Gautam JoEllyn M. McMillan Devendra Kumar Aditya N. Bade Qiaoyu Pan Tanmay A. Kulkarni Wenkuan Li Brady Sillman Nathan A. Smith Bhagya L. Dyavar Shetty Adam Szlachetka Benson J. Edagwa Howard E. Gendelman Yazen Alnouti |
| author_facet |
Nagsen Gautam JoEllyn M. McMillan Devendra Kumar Aditya N. Bade Qiaoyu Pan Tanmay A. Kulkarni Wenkuan Li Brady Sillman Nathan A. Smith Bhagya L. Dyavar Shetty Adam Szlachetka Benson J. Edagwa Howard E. Gendelman Yazen Alnouti |
| author_sort |
Nagsen Gautam |
| title |
Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir |
| title_short |
Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir |
| title_full |
Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir |
| title_fullStr |
Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir |
| title_full_unstemmed |
Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir |
| title_sort |
lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/2bfe8aa999a043d6aa5d494a5ae8099d |
| work_keys_str_mv |
AT nagsengautam lipophilicnanocrystalprodrugreleasedefinestheextendedpharmacokineticprofilesofayearlongcabotegravir AT joellynmmcmillan lipophilicnanocrystalprodrugreleasedefinestheextendedpharmacokineticprofilesofayearlongcabotegravir AT devendrakumar lipophilicnanocrystalprodrugreleasedefinestheextendedpharmacokineticprofilesofayearlongcabotegravir AT adityanbade lipophilicnanocrystalprodrugreleasedefinestheextendedpharmacokineticprofilesofayearlongcabotegravir AT qiaoyupan lipophilicnanocrystalprodrugreleasedefinestheextendedpharmacokineticprofilesofayearlongcabotegravir AT tanmayakulkarni lipophilicnanocrystalprodrugreleasedefinestheextendedpharmacokineticprofilesofayearlongcabotegravir AT wenkuanli lipophilicnanocrystalprodrugreleasedefinestheextendedpharmacokineticprofilesofayearlongcabotegravir AT bradysillman lipophilicnanocrystalprodrugreleasedefinestheextendedpharmacokineticprofilesofayearlongcabotegravir AT nathanasmith lipophilicnanocrystalprodrugreleasedefinestheextendedpharmacokineticprofilesofayearlongcabotegravir AT bhagyaldyavarshetty lipophilicnanocrystalprodrugreleasedefinestheextendedpharmacokineticprofilesofayearlongcabotegravir AT adamszlachetka lipophilicnanocrystalprodrugreleasedefinestheextendedpharmacokineticprofilesofayearlongcabotegravir AT bensonjedagwa lipophilicnanocrystalprodrugreleasedefinestheextendedpharmacokineticprofilesofayearlongcabotegravir AT howardegendelman lipophilicnanocrystalprodrugreleasedefinestheextendedpharmacokineticprofilesofayearlongcabotegravir AT yazenalnouti lipophilicnanocrystalprodrugreleasedefinestheextendedpharmacokineticprofilesofayearlongcabotegravir |
| _version_ |
1718389314578022400 |